Vaxcyte Mission

Seeking to improve global health by developing potentially superior and novel vaccines designed to prevent or treat the most common and deadly infectious diseases worldwide.

This is Salient

Stop blending in & start leaving your mark on the web

View Our Work
Learn About Us
 

Vaxcyte

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

 

Vaxcyte

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

 

Vaxcyte

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

 

Vaxcyte

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

 

Experience

What real creative freedom feels like in a theme

Learn More Now
View Work Instead

Pixel Perfection

Salient was built with a high attention to details both in design & code

Platform

Exclusive license to XpressCF™, an industrialized cell-free protein synthesis platform, for the vaccine field allowing: (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.

People

Assemblage of preeminent vaccinologists, vaccine developers & biotech company-builders joined together to harness the platform to create positive synergies to optimize development.

Vaccines

Endeavoring to deliver potentially superior and novel vaccines, beginning with its lead program: A broad-spectrum pneumococcal conjugate vaccine.

Well-Financed

Backed by a world-class syndicate of private equity, venture capital, institutional & corporate venture investors with over $280M in capital raised since inception.

Join Our Team, Change the Shape of Vaccine Research View Open Positions